lavoltidine
Sign in to saveAlso known as loxtidine
Lavoltidine (INN, USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
Research
1 papers- Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.Pharmacology & therapeutics · 1997
via PubMed
Wikidata facts
- Mass
- 359.232
Show 4 more facts
- chemical formula
- C₁₉H₂₉N₅O₂
- canonical SMILES
- CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3
- Commons category
- Lavoltidine
- World Health Organisation international non-proprietary name
- lavoltidine
Sources (2)
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- See also
- References
Lavoltidine (INN, USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.
==See also== H2 receptor antagonist Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)